XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.26.1

SALE OF ASSETS | 3 Months Ended
--- | ---
Mar. 31, 2026
Sale Of Assets |
SALE OF ASSETS | NOTE 18 – SALE OF ASSETS On June 29, 2023, the Company completed a transaction whereby it sold assets related to its Integrated Correctional Automation System (iCAS) business with a single customer. In the fourth quarter of 2022, the Company elected to not renew a support contract due to the limited nature of the business. The transaction was completed with a third-party buyer of which the Company’s former Chief Financial Officer (until November 2025) and now current Strategic Advisor is a director. The former officer did not participate in the transaction on behalf of the Company which was negotiated by the CEO. The assets of the iCAS business were sold for a convertible promissory note with a principal amount of $165,000 with a 10% original issue discount as well as common stock purchase warrants. The note originally matured in 2 years from the date of sale and is convertible immediately through the later of the maturity date or payment by the borrower of the default amount, as defined in the note, into shares of the buyer’s common stock at a conversion price of $0.003 or 55,000,000 shares. The conversion of the note carries restrictions which include limiting conversion to the extent it would not exceed 4.99% of the common stock outstanding of the buyer. The convertible promissory note is subject to standard anti-dilution provisions. In June 2025, the Company and the borrower amended the convertible promissory note increasing the principal amount to $180,000 and extending the maturity date to June 29, 2027. There was no change to other terms and conditions. In July 2025, the Company and the borrower agreed to a further 2-year extension of the note at the same terms and conditions. The iCAS note receivable was fully reserved in accordance with management’s assessment. The common stock purchase warrants are for a total of 55,000,000 common shares of the buyer at an exercise price of $0.01 per share. The warrants are subject to standard anti-dilution provisions. The warrants were not exercisable until on or after six months from the issuance date and no later than on or before the third anniversary of the issuance date. The Company may exercise the warrants at any time after the six-month anniversary of the issuance date on a cashless basis if there is no effective registration statement covering the resale of the Warrant Shares at prevailing market prices by the holder. The exercise of these warrants is subject to beneficial ownership limits of 4.99% which may be increased by the holder up to 9.99% as defined in the warrant. Given that the shares carried no intrinsic value at the time of the transaction and that the overall fair value is de minimis, the Company has not recorded the warrants associated with the transaction. As of the date of this filing, the Company continues to hold the warrants. The original issue discount was accrued into interest income over the term of the note. The note receivable was recorded as follows on March 31, 2026 and December 31, 2025:
Schedule of note receivable |  |  |  |  |  |
|  | March 31, 2026 |  |  | December 31, 2025 |
Convertible note receivable |  | $ | 180,000 |  |  | $ | 180,000 |
Less allowance on note receivable |  |  | (180,000 | ) |  |  | (180,000 | )
Convertible note receivable, net |  | $ | — |  |  | $ | — |

X
- References No definition available. + Details
Name: | duot_DisclosureSaleOfAssetsAbstract
Namespace Prefix: | duot_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | duot_SaleOfAssetsTextBlock
Namespace Prefix: | duot_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration